BNOX vs. TFFP, BFRI, CMMB, ASLN, KTTA, KA, LIXT, GRAY, EFTR, and CANF
Should you be buying Bionomics stock or one of its competitors? The main competitors of Bionomics include TFF Pharmaceuticals (TFFP), Biofrontera (BFRI), Chemomab Therapeutics (CMMB), ASLAN Pharmaceuticals (ASLN), Pasithea Therapeutics (KTTA), Kineta (KA), Lixte Biotechnology (LIXT), Graybug Vision (GRAY), eFFECTOR Therapeutics (EFTR), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical preparations" industry.
TFF Pharmaceuticals (NASDAQ:TFFP) and Bionomics (NASDAQ:BNOX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.
TFF Pharmaceuticals presently has a consensus price target of $72.00, indicating a potential upside of 2,260.66%. Bionomics has a consensus price target of $9.00, indicating a potential upside of 831.39%. Given Bionomics' higher possible upside, research analysts plainly believe TFF Pharmaceuticals is more favorable than Bionomics.
TFF Pharmaceuticals has higher revenue and earnings than Bionomics.
Bionomics has a net margin of 0.00% compared to Bionomics' net margin of -2,897.95%. TFF Pharmaceuticals' return on equity of 0.00% beat Bionomics' return on equity.
TFF Pharmaceuticals received 51 more outperform votes than Bionomics when rated by MarketBeat users. However, 72.73% of users gave Bionomics an outperform vote while only 67.68% of users gave TFF Pharmaceuticals an outperform vote.
TFF Pharmaceuticals has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Bionomics has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500.
15.3% of TFF Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.9% of Bionomics shares are owned by institutional investors. 5.6% of TFF Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Bionomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, TFF Pharmaceuticals and TFF Pharmaceuticals both had 1 articles in the media. Bionomics' average media sentiment score of 0.00 equaled TFF Pharmaceuticals'average media sentiment score.
Summary
Bionomics beats TFF Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Bionomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNOX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionomics Competitors List
Related Companies and Tools
